The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...
Saad Z. Usmani, MD, MBA, FACP, myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center, presented the results of the CEPHEUS trial and emphasized the positive impact ...
Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...
Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...
2d
Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...
Venus still hovers low in the southwestern sky at dusk a half-hour to 45 minutes after sunset. Saturn is comfortably high up ...
The International Space Station will be making a few visible evening passes through Santa Barbara’s skies over the next week ...
The “once & hopeful stars” are here because 1708 Executive Director Emily Smith emailed Seipel, a co-founder of the Broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback